CTLA4 and neoplasm: Thus, in tumors with low glycolytic activity (i.e., higher glucose availability for infiltrating immune cells), anti-CTLA4 blockade improves anti-tumor immune responses by permitting increased glycolysis; this is beneficial for CD8+ T cell activation and effector function but is detrimental to Treg cell stability [86].